A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myeloma

Detalles Bibliográficos
Autores principales: Lee, Hans C., Shah, Jatin J., Feng, Lei, Manasanch, Elisabet E., Lu, Rebecca, Morphey, Ashley, Crumpton, Brandon, Patel, Krina K., Wang, Michael L., Alexanian, Raymond, Thomas, Sheeba K., Weber, Donna M., Orlowski, Robert Z.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6773683/
https://www.ncbi.nlm.nih.gov/pubmed/31575851
http://dx.doi.org/10.1038/s41408-019-0240-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6773683/
https://www.ncbi.nlm.nih.gov/pubmed/31575851
http://dx.doi.org/10.1038/s41408-019-0240-6

Ejemplares similares